Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance

Neurocrine Biosciences IncTrade
YieldMax Universe Fund of Option Income ETFsTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B), while YieldMax Universe Fund of Option Income ETFs trades at $7.63. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.

NBIXYMAX
Market Cap
$16.46B
Sector
HealthIncome / Options Overlay
52-Week High
$185.50$13.26
52-Week Low
$123.10$7.27
Enterprise Value
$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.

Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.

YieldMax Universe Fund of Option Income ETFs

YMAX trades at $7.63, down 1.04% in the past 24 hours, with technical indicators showing a bullish overall signal but bearish moving averages. The fund has announced consistent weekly dividend distributions, though recent news highlights concerns over fee structures impacting payouts. Key support is at $7, with resistance at $8.

The outlook for YMAX hinges on its ability to sustain dividend yields amid fee pressures; opportunities include high income generation, but risks involve cost inefficiencies and market volatility. Analyst sentiment is mixed, balancing yield appeal against structural drawbacks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About YieldMax Universe Fund of Option Income ETFs

YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.

Read more on YMAX